Page 12:
Achieving voluntary enrolment into the trial has proven to be much more challenging than was anticipated by Neuren and the US Army. All aspects of the trial design and execution are currently under review to determine the best way forward.
I would be surprised if we managed to get results for the concussion trial in 2016.
- Forums
- ASX - By Stock
- NEU
- Ann: Annual Report to shareholders-NEU.AX
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.00%
!
$12.85

Ann: Annual Report to shareholders-NEU.AX, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.85 |
Change
0.000(0.00%) |
Mkt cap ! $1.598B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16 | $14.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.07 | 68 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16 | 14.070 |
6 | 302 | 13.630 |
7 | 749 | 13.490 |
1 | 2 | 13.240 |
1 | 1 | 13.050 |
Price($) | Vol. | No. |
---|---|---|
12.070 | 1 | 1 |
12.220 | 630 | 3 |
12.480 | 38 | 1 |
12.710 | 705 | 1 |
12.850 | 944 | 3 |
Last trade - 09.53am 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online